| Literature DB >> 25445023 |
Sally Arai1, Mukta Arora2, Tao Wang3, Stephen R Spellman4, Wensheng He5, Daniel R Couriel6, Alvaro Urbano-Ispizua7, Corey S Cutler8, Andrea A Bacigalupo9, Minoo Battiwalla10, Mary E Flowers11, Mark B Juckett12, Stephanie J Lee13, Alison W Loren14, Thomas R Klumpp15, Susan E Prockup16, Olle T H Ringdén17, Bipin N Savani18, Gérard Socié19, Kirk R Schultz20, Thomas Spitzer21, Takanori Teshima22, Christopher N Bredeson23, David A Jacobsohn24, Robert J Hayashi25, William R Drobyski26, Haydar A Frangoul27, Görgün Akpek28, Vincent T Ho8, Victor A Lewis29, Robert Peter Gale30, John Koreth8, Nelson J Chao31, Mahmoud D Aljurf32, Brenda W Cooper33, Mary J Laughlin34, Jack W Hsu35, Peiman Hematti12, Leo F Verdonck36, Melhelm M Solh37, Maxim Norkin35, Vijay Reddy38, Rodrigo Martino39, Shahinaz Gadalla40, Jenna D Goldberg41, Philip L McCarthy42, José A Pérez-Simón43, Nandita Khera44, Ian D Lewis45, Yoshiko Atsuta46, Richard F Olsson47, Wael Saber5, Edmund K Waller48, Didier Blaise49, Joseph A Pidala50, Paul J Martin13, Prakash Satwani51, Martin Bornhäuser52, Yoshihiro Inamoto13, Daniel J Weisdorf2, Mary M Horowitz5, Steven Z Pavletic53.
Abstract
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P < .0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.Entities:
Keywords: Allogeneic transplant; Incidence; Nonrelapse mortality; cGVHD
Mesh:
Substances:
Year: 2014 PMID: 25445023 PMCID: PMC4326247 DOI: 10.1016/j.bbmt.2014.10.021
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742